SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis — Stella

Recruiting

Back to HCC trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

Hong Kong

Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong

Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong

Key details

Phase

Safety & dosing

Sponsor

Chinese University of Hong Kong

Enrollment target

~40 participants

Started

July 2025

Primary completion

July 2027

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov